Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer

Jing, Jiexian; Wang, Yan; Xu, Ximing; Sun, Tao; Tian, Bailing; Du, Liqing; Zhao, Xianxian; Han, Chen

doi:10.7314/apjcp.2014.15.23.10267

Cited by 42 publications

(25 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several of the most frequently used tumor markers, including carbohydrate antigen (CA)724, CA199, carcinoembryonic antigen (CEA) and CA242, have been confirmed to jointly provide information aiding in the diagnosis, classification, prognosis and treatment selection in gastric cancer (18)(19)(20)(21), while the value of information provided by of any of them alone is low. Jing et al (22) found that the sensitivity of CA724, CA199, CEA and CA242 was only 25.4, 36.2, 26.8 and 42.9%, respectively. Therefore, it is desirable to identify novel biomarkers with high sensitivity and specificity.…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of serum tumor abnormal protein in gastric cancer patients

Feng

Zhu

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Aberrant glycosylation of protein occurs in nearly all types of cancers and has been confirmed to be associated with tumor progression, metastasis and the survival rate of patients. The present study aimed to explore the prognostic value of tumor abnormal protein (TAP) in gastric cancer patients. TAP was detected in the blood of 42 gastric cancer patients and 56 healthy volunteers by using the TAP testing kit. Univariate and multivariate Cox regression analysis were performed to evaluate the prognostic value of TAP. In total, 64.3% of gastric cancer patients were positive for TAP, and TAP was significantly correlated with poor prognosis [progression-free survival (PFS), 4.2 vs. 12.6 months; P= 0.043]. TAP [hazard ratio (HR), 64.487; P<0.01), differentiation (HR, 17.279; P<0.01) and TNM stage (HR, 45.480; P<0.01) were found to be independent predictive factors for PFS. Furthermore, Kaplan-Meier curves indicated that TAP is associated with a reduced PFS in gastric cancer patients. The results of the present study therefore indicated that the TAP test has significant prognostic value for gastric cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic value of serum tumor abnormal protein in gastric cancer patients

Feng

Zhu

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…However, each TM has its limitation in terms of diagnostic value, particularly for early diagnosis. [16] It is therefore necessary to identify new combination models of TMs.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer

et al. 2016

View full text Add to dashboard Cite

AimsTo evaluate the clinical significance of multiple serum tumor markers (TMs) in the diagnosis of gastric cancer (GC) and establish an accurate discriminant equation to identify the presence of GC.ResultsThe serum levels of CEA, CA19-9 and CA72-4 were higher in the GC group than in the control group (P < 0.005). The sensitivity of CEA, CA19-9 and CA72-4 in the diagnosis of GC was 20.1–27.6% individually and increased to 48.2% when they were considered in combination. By using the optimal cut-off value, the sensitivity of CEA, CA19-9 and CA72-4 for the diagnosis of GC was improved but remained unsatisfactory. In addition, we developed the equation Y = −2.185 − 0.015 X1 + 0.180 X2 + 1.226 X3 + 1.505 X4 + 2.749 X5 (X1 = Age, X2 = Sex, X3 =CEA, X4 = CA19-9 and X5 = CA72-4) to predict the presence of GC. This has better accuracy and diagnostic efficiency compared to the combination of TMs.MethodsSerum carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9)and cancer antigen 72-4 (CA72-4) levels were measured in a total of 2288 patients with GC and 1869 healthy volunteers or patients with benign gastric diseases. We established a diagnostic equation using a portion of the data (training set), and validate its accuracy using the other portion of the data (testing set).ConclusionsThe diagnostic equation increases the accuracy rate for the diagnosis of GC and will be helpful in the clinic.

show abstract

“…However, their clinical use is limited by low sensitivity and specificity [4, 5]. Easier, more sensitive, and noninvasive tumor marker assays are urgently needed to improve screening, diagnosis, prognostic evaluation, recurrence monitoring, and follow-up observation of therapeutic efficiency.…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer

et al. 2016

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) have recently emerged as vital players in tumor biology with potential value in cancer diagnosis, prognosis, and therapeutics. The lncRNA HULC (highly up-regulated in liver cancer) is increased in many malignancies, yet its serum expression profile and clinical value in gastric cancer (GC) patients remain unclear. Quantitative real-time polymerase chain reaction (RT-qPCR) for large-scale analysis of the serum expression of HULC in GC patients reliably detected circulating HULC and revealed that it is upregulated in GC patients. A high serum HULC level correlated with tumor size, lymph node metastasis, distant metastasis, tumor-node-metastasis stage, and H. pylori infection. The area under the ROC curve for HULC was up to 0.888, which was higher than that for CEA (0.694) and CA72-4 (0.514). Follow-up detection and Kaplan-Meier curve analysis revealed HULC is a good predictor of GC prognosis. Our present study indicates that circulating HULC may represent a novel serum tumor marker for early diagnosis and monitoring progression and prognosis of GC.

show abstract

Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer

Cited by 42 publications

References 27 publications

Prognostic value of serum tumor abnormal protein in gastric cancer patients

Prognostic value of serum tumor abnormal protein in gastric cancer patients

Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer

Long non-coding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer

Contact Info

Product

Resources

About